

FEB 2 4 2004 BY IN TH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David Jonathan Madge et al.

Application No. 10/659,178

Filed: September 9, 2003

Confirmation No. 7469

For: BORONIC ACID SALTS

Examiner: To be assigned

Art Unit: 1621

Attorney Reference No. 6613-66750

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are beingdeposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney

for Applicant(s)

Date Mailed February 20, 2004

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☐ Information Disclosure Statement
 ☐ Form PTO-1449 and references cited thereon
- The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Ву

Wayne∕W. Ruper

Registration No. 34,420

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re application of: David Jonathan Madge et al.

Application No. 10/659,178 Filed: September 9, 2003 Confirmation No. 7469

BORONIC ACID SALTS For:

Examiner: To be assigned

Art Unit: 1621

Attorney Reference No. 6613-66750

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS. P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney

for Applicant(s

Date Mailed February 20

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

ayne/W. Rupert

Registration No. 34,420

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

FEB 2 4 2004

TOTO THE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66750
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		4,499,082	12 Feb 1985	Shenvi et al.
		4,701,545	20 Oct 1987	Matteson et al.
		4,935,493	19 Jun 1990	Bachovchin et al.
		4,963,655	16 Oct 1990	Kinder et al.
		5,187,157	16 Feb 1993	Kettner et al.
		5,444,049	22 Aug 1995	de Nanteuil et al.
		5,462,964	31 Oct 1995	Fevig et al.
.,		5,563,127	08 Oct 1996	Amparo et al.
	<u>-</u>	5,574,014	12 Nov 1996	Claeson et al.
		5,585,360	17 Dec 1996	de Nanteuil et al.
		5,658,885	19 Aug 1997	Lee et al.
		5,681,978	28 Oct 1997	Matteson et al.
		5,731,439	24 Mar 1998	Carini et al.
		5,780,454	14 Jul 1998	Adams et al.
		5,814,622	29 Sep 1998	de Nanteuil et al.
		6,066,730	23 May 2000	Adams et al.
		6,313,096	06 Nov 2001	Claeson et al.

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number	6613-66750
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

15 Oct 2002 6,465,433 Adams et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		0471651	19 Feb 1992	EPC
		WO 92/07869	14 May 1992	WIPO/PCT
		WO 94/21650	29 Sep 1994	WIPO/PCT
		WO 94/25049	10 Nov 1994	WIPO/PCT
2		WO 95/09634	13 Apr 1995	WIPO/PCT
		WO 95/09858	13 Apr 1995	WIPO/PCT
•		WO 95/09859	13 Apr 1995	WIPO/PCT
		WO 96/13266	09 May 1996	WIPO/PCT
		WO 96/20689	11 Jul 1996	WIPO/PCT
		WO 97/05161	13 Feb 1997	WIPO/PCT
		WO 98/31688	23 Jul 1998	WIPO/PCT
		WO 99/26652	03 Jun 1999	WIPO/PCT
		WO 00/35904	22 Jun 2000	WIPO/PCT
		WO 00/35905	22 Jun 2000	WIPO/PCT
		WO 00/41715	20 Jul 2000	WIPO/PCT
		WO 01/41796	14 Jun 2001	WIPO/PCT

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
SIGNATURE.	CONSIDERED.
	<u> </u>

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

-66750				
59,178				
ember 9, 2003				
d Jonathan Madge				
e assigned				
O. OTHER DOCUMENTS				
Claeson et al., "Novel peptide mimetics as highly efficient inhibitors of thrombin based on modified D-Phe-Pro-Arg sequences," in Peptides, Chemistry and Biology, Smith J A, Rivier J E, Eds., Escom: Leiden pp. 824-825, 1992. Claeson et al., Biochem J. 290:309-312, 1993. Claeson et al., The Design of Synthetic Inhibitors of Thrombin 340:83-89, 1993. Claeson, Blood Coagulation and Fibrinolysis 5:411-436, 1994.				
Coburn, Exp. Opin. Ther. Patents 11(5):721-738, 2001.				
Contreras et al., J. Org. Chem. 246:213-217, 1983.				
Deadman et al., J. Medicinal Chemistry 38:1511-1522, 1995.				
Deadman et al., J. Enzyme Inhibition 9:29-41, 1995.				
Elgendy et al., Thromb Haemostas 65:775, 1991.				
Elgendy et al., Tetrahedron Letters 33(29):4209-4212, 1992.				
Elgendy et al., The Design of Synthetic Inhibitors of Thrombin 340:173-178, 1993.				
Elgendy et al., Tetrahedron 50(12):3803-3812, 1994.				

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORMATION DISCLOSURE STATEMENT				
BY APPLICANT				

Attorney Docket Number	6613-66750
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

		Art Unit	1621		
		Examiner Name			
· · · · · · · · · · · · · · · · · · ·			To be assigned		
	Esmail et al., Thrombosis and H	laemostasis 6:1318, 1995.			
	Esmail et al., Thrombosis and Haemostasis 5:91-92, 1997. Esmail et al., Thrombosis and Haemostasis 5:498-499, 1997. Gerrard et al., Thrombosis and Haemostasis 6:1307, 1995. Gustafsson et al., Thrombosis Research 101:171-181, 2001.				
	Katz et al., Biochemistry 34(26)	:8264-8280, 1995.	· · · · · · · · · · · · · · · · · · ·		
	Martichonok et al., J. Am. Chem	soc. 118:950-958, 1996.			
•	Matt et al., Bioorg. Med. Chem.	Matt et al., Bioorg. Med. Chem. 8:2291-2303, 2000.			
	Matteson, Chem. Rev. 89:1535-	1551, 1989.			
	Matteson et al., J. Org. Chem. 61:6047-6051, 1996.				
	Metternich et al., Naunyn-Schmiedeberg's Arch Pharmocol 97:345, 1992.				
	Philipp et al., The Design of Synthetic Inhibitors of Thrombin 340:67-77, 1993.				
	Rewinkel et al., Current Pharmaceutical Design 5:1043-1075, 1999.				
	Saitoh et al., Pharmaceutical Research 16(11):1786-1789, 1999.				
	Sanderson et al., Current Medicinal Chemistry 5:289-304, 1998.				
	Skordalakes et al., <i>Biochemistry</i> 37(41):14420-14427, 1998.				
	Spencer et al., <i>Tetrahedron</i> 58:1551-1556, 2002.				
	Stahl et al., <i>Handbook of Pharmaceutical Salts Properties, Selection, and Use</i> , Verlag Helvetica Chimica Acta, Postfach, CH-8042 Züirch, Switzerland, 2002.				
	Tapparelli et al., "The Journal of Biological Chemistry 268(7):4734-4741, 1993.				

EXAMINER DATE CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORMATION DISCLOSURE STATEMENT	
BY APPLICANT	

Attorney Docket Number	6613-66750		
Application Number	10/659,178		
Filing Date	September 9, 2003		
First Named Inventor	David Jonathan Madge		
Art Unit	1621		
Examiner Name	To be assigned		

		- F	A 4 TT *4	1601	
			Art Unit	1621	
		ŀ	Examiner Name	To be assigned	
	Tapparelli et al., Trends Pharmacol. Sci. 14:366-376, 1993.				
	Trigen Limited, TRI 50b Non Confidential Information pp. 1-12, July 2002.				
	Trigen Limited, "Looking for a career in Biotechnology?" poster exhibited at XVIIth International Symposium on Medicinal Chemistry, Barcelona, Spain, September 5, 2002.				
	Tripathy et al., Synthesis pp. 200-206, 1990.				
	Wu et al., Journal of Pharmaceutical Sciences 89(6):758-765, June 2000.				
	Yang et al., Pharmaceutical Research 16(9):1331-1343, 1999.				
1	Yang et al., Medicinal Research Reviews 23(3):346-368, 2003.				
•	•		·		

		-			
	· · · · · · · · · · · · · · · · · · ·				

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.